Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating ...
A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer
United States Gil Efron Michael Schickler Exchange Commission American Society Of Clinical Oncology Company Contact
Source: djournal.com